General Medical Necessity
Coverage requires that the requested therapy be medically necessary and supported by current authoritative evidence.
ALL of the following
The requested therapy is proven effective for the member's relevant diagnosis or procedure.
For drug therapy, the proposed dose, frequency, and duration are consistent with recommendations in at least one authoritative source, such as FDA-approved labeling, nationally recognized drug compendia, peer-reviewed literature, generally accepted standards of care, professional society guidelines, or applicable CMS coverage policy.
Initial Therapy: X-Linked Hypophosphatemia
Burosumab-twza (Crysvita) may be considered medically necessary for individuals 6 months of age and older with X-linked hypophosphatemia when ALL of the following are met:
ALL of the following
Diagnosis of XLH is confirmed by ONE of the following
PHEX genetic testing confirms XLH.
Serum fibroblast growth factor 23 (FGF23) level is elevated.
Fasting serum phosphorus is below the normal range for the patient's age.
Clinical signs or symptoms of XLH are present, such as rickets, growth retardation, musculoskeletal pain, or bone fractures.
The member does not have severe renal impairment or end-stage renal disease, defined for this coverage criterion as a glomerular filtration rate below 30 mL/min.
Oral phosphate and active vitamin D analogs have been discontinued at least 1 week before initiation of burosumab-twza.
Initial Therapy: Tumor-Induced Osteomalacia
Burosumab-twza (Crysvita) may be considered medically necessary for individuals 2 years of age and older with FGF23-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors when ALL of the following are met:
ALL of the following
Tumor-induced osteomalacia is diagnosed and confirmed by an elevated serum fibroblast growth factor 23 (FGF23) level.
Fasting serum phosphorus is below the normal range for the patient's age.
The member does not have severe renal impairment or end-stage renal disease, defined for this coverage criterion as a glomerular filtration rate below 30 mL/min.
Oral phosphate and active vitamin D analogs have been discontinued at least 2 weeks before initiation of burosumab-twza.
The phosphaturic mesenchymal tumor cannot be curatively resected or localized.
Therapy Interruption and Reassessment
Treatment must be interrupted and reassessed when the underlying tumor is treated.
ALL of the following
If the member undergoes treatment of the underlying tumor, including surgical excision or radiation therapy, burosumab-twza is interrupted after treatment is completed.
Serum phosphorus is reassessed after treatment of the underlying tumor.
If serum phosphorus remains below the lower limit of normal, burosumab-twza is restarted at the initiation dose; subsequent dose adjustment follows the FDA label to maintain serum phosphorus within the age-specific reference range.
FDA-Labeled Indications
Coverage is limited to FDA-labeled indications and labeled age groups.
ONE of the following FDA-labeled indications
X-linked hypophosphatemia (XLH) in adult or pediatric patients 6 months of age and older.>= 6 months
FGF23-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized, in adult or pediatric patients 2 years of age and older.>= 2 years
Contraindication Screening
Screen for all FDA-labeled contraindications and excluded clinical circumstances before initiation or continuation.
ALL of the following must be absent
Severe renal impairment or end-stage renal disease.
Serum phosphorus within or above the normal range for the patient's age.
Concomitant use of oral phosphate or active vitamin D analogs.
X-Linked Hypophosphatemia — Medical Necessity Coverage Pathway
Coverage pathway for XLH:
Coverage requires ALL of the following
The member is 6 months of age or older and has XLH.
The applicable XLH diagnostic, laboratory, clinical, renal, and medication-discontinuation criteria are met.
Tumor-Induced Osteomalacia — Medical Necessity Coverage Pathway
Coverage pathway for TIO:
Coverage requires ALL of the following
The member is 2 years of age or older and has FGF23-related hypophosphatemia in tumor-induced osteomalacia associated with a phosphaturic mesenchymal tumor.
The applicable TIO diagnostic, laboratory, renal, medication-discontinuation, and tumor-resectability criteria are met.
State regulations and the member contract must be reviewed. For members residing in Ohio, Ohio Revised Code § 3923.60 requires group or individual policies that cover prescription drugs to cover an FDA-approved drug when prescribed for a use recognized as safe and effective for the indication in an adopted standard medical reference compendium or in medical literature, even when the use is not FDA-approved. Medical-literature support requires safety and efficacy confirmed in two articles from major peer-reviewed professional medical journals. Evidence limited to case reports or case series is insufficient. Coverage is never required for an FDA-recognized contraindicated use or for non-formulary drugs.
Burosumab-twza is excluded in members with severe renal impairment or end-stage renal disease. For this policy, severe renal impairment is defined as a glomerular filtration rate below 30 mL/min.
Burosumab-twza is contraindicated when serum phosphorus is within or above the normal range for the patient's age because increases above the upper limit of normal may increase the risk of nephrocalcinosis.
Burosumab-twza must not be used with oral phosphate or active vitamin D analogs. These therapies must be discontinued before initiation.
Contraindicated concomitant therapies include oral phosphate and active vitamin D analogs, including calcitriol, paricalcitol, doxercalciferol, and calcifediol. The FDA recommends discontinuing these therapies 1 week before initiation.
Crysvita is contraindicated when serum phosphorus is within or above the normal range for the patient's age. Dose interruption or reduction may be required based on serum phosphorus levels; patients with TIO who undergo treatment of the underlying tumor should have dosing interrupted and adjusted to prevent hyperphosphatemia.
Crysvita is contraindicated in severe renal impairment or end-stage renal disease. For pediatric patients, this includes estimated GFR 15–29 mL/min/1.73 m² or end-stage renal disease (eGFR below 15 mL/min/1.73 m²). For adults, this includes creatinine clearance 15–29 mL/min or end-stage renal disease (creatinine clearance below 15 mL/min).
Safety and effectiveness have not been established for XLH in pediatric patients below 6 months of age. Safety and effectiveness have not been established for TIO in pediatric patients below 2 years of age. Use below these labeled ages is not covered.
Burosumab-twza is considered experimental, investigational, and/or unproven for all other non-FDA-approved indications.
Burosumab-twza is considered experimental, investigational, and/or unproven when the applicable coverage criteria are not met or when it is requested for a non-FDA-approved indication.